Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003352 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast Cancer
A Phase 2 study, sponsored by NSABP Foundation.
- Completed
- Registry status
- Phase 2
- Development phase
- 89
- Enrollment target
NCT00003352 is a Phase 2 study that has completed, run by NSABP Foundation. The registered enrollment target is 89 participants.
The verdict
NCT00003352, a Phase 2 study, has completed, sponsored by NSABP Foundation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 89 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy consisting of doxorubicin, cyclophosphamide, and docetaxel in treating women with stage IIIB or stage IV breast cancer.
Interventions
- DRUG Taxotere
- DRUG cyclophosphamide
- DRUG Adriamycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 1998-06 |
| Est. Completion | 2002-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003352
The ClinicalTrials.gov registry entry for NCT00003352 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NSABP Foundation, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Taxotere is the first listed.
NCT00003352 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003352 about?
NCT00003352 is a clinical study titled "Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy consisting of doxorubicin, cyclophosphamide,...
What is the current status of trial NCT00003352?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 89 participants. The study started on 1998-06. Estimated completion is 2002-12.
What interventions are being tested in trial NCT00003352?
The interventions under investigation include: Taxotere (DRUG), cyclophosphamide (DRUG), Adriamycin (DRUG).
Who is sponsoring clinical trial NCT00003352?
This trial is sponsored by NSABP Foundation, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.